Examinations
Examinations
Triple Test (20–21 Weeks, Singleton Pregnancy)
The triple test is a second-trimester screening conducted between 20 and 21 weeks of pregnancy to evaluate the risk of chromosomal abnormalities and neural tube defects in the fetus.
Tested Parameters
- Alpha-fetoprotein (AFP) – A protein produced by the fetal liver that gradually increases in maternal blood during pregnancy.
- Human Chorionic Gonadotropin (hCG) – A hormone produced by the placenta that starts increasing from early pregnancy.
- Unconjugated Estriol (uE3) – A hormone produced by both the fetus and the placenta.
- Avoid fatty foods for 24 hours before testing.
- Avoid physical and emotional stress for 30 minutes before testing.
- Do not smoke for at least 30 minutes before the test.
- Bring ultrasound results from the last 24 hours for more accurate risk calculation.
Who Should Take the Triple Test?
- Women aged 35 years or older.
- Those who used harmful medications during pregnancy.
- Women with diabetes.
- Those who had a viral infection during pregnancy.
- Women with a family history of congenital defects.
- Those who have a child with congenital defects.
The triple screening test provides information on whether there is an increased risk of Down syndrome (Trisomy 21), Edwards syndrome (Trisomy 18), Patau syndrome (Trisomy 13), and neural tube defects. The results are assessed by a doctor to determine if further diagnostic testing is necessary